We are analyzing https://link.springer.com/article/10.1007/bf02244871.

Title:
Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety | Psychopharmacology
Description:
The elevated “zero-maze” is a modification of the elevated plus-maze model of anxiety in rats which incorporates both traditional and novel ethological measures in the analysis of drug effects. The novel design comprises an elevated annular platform with two opposite enclosed quadrants and two open, removing any ambiguity in interpretation of time spent on the central square of the traditional design and allowing uninterrupted exploration. Using this model, the reference benzodiazepine anxiolytics, diazepam (0.125–0.5 mg/kg) and chlordiazepoxide (0.5–2.0 mg/kg) significantly increased the percentage of time spent in the open quadrants (% TO) and the frequency of head dips over the edge of the platform (HDIPS), and reduced the frequency of stretched attend postures (SAP) from the closed to open quadrants. In contrast, the anxiogenic drugm-chlorophenyl-piperazine (mCPP; 0.25–1.0 mg/kg) induced the opposite effects, decreasing %TO and HDIPS, and increasing SAP. The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.001–0.1 mg/kg) had no effects on either %TO or HDIPS, but did decrease SAP at 0.01 mg/kg although not at higher or lower doses. Similarly, the 5-HT3 receptor antagonist, ondansetron (0.0001–1.0 mg/kg) decreased SAP and increased %TO at 0.01 mg/kg, but not at other doses. The present data suggest that a combination of the novel “zero-maze” design and a detailed ethological analysis provides a sensitive model for the detection of anxiolytic/anxiogenic drug action.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Social Networks
Video & Online Content

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We don’t know how the website earns money.

The purpose of some websites isn't monetary gain; they're meant to inform, educate, or foster collaboration. Everyone has unique reasons for building websites. This could be an example. Link.springer.com might have a hidden revenue stream, but it's not something we can detect.

Keywords {🔍}

google, scholar, elevated, effects, anxiety, pharmacol, plusmaze, psychopharmacology, receptor, test, hta, antagonists, rodgers, article, rat, behav, behavioural, animal, model, rats, agonists, shepherd, diazepam, anxiolytic, receptors, zeromaze, mgkg, file, dourish, drug, models, eds, xmaze, behaviour, serotonin, privacy, cookies, content, open, benzodiazepine, stretched, attend, sap, mcpp, ohdpat, antagonist, activity, behavior, benzodiazepines, biochem,

Topics {✒️}

month download article/chapter m-chlorophenylpiperazine enhances neophobic anxiogenic drugm-chlorophenyl-piperazine conflict-reducing drug action stretched attend postures anxiolytic/anxiogenic drug action anxiety/defense test battery stretched attend posture privacy choices/manage cookies full article pdf drug discrimination studies rat elevated x-maze head dips related subjects 5-ht1b characterizing agents antipredator defense reactions x-maze anxiety model article psychopharmacology aims opiate receptor manipulations european economic area allowing uninterrupted exploration di-n-propylamino fluoren-9-ol hydrochloride bax/bcl-2 proteins dorsal raphe lesions wrightson biomedical publications cobain mr daly huntercombe lane south comparative behavioural pharmacology present data suggest conditions privacy policy september 1994 volume 116 5-ht1a selective ligand anxiogenic endogenous ligand anxiogenic drug effects introductory statistical methods 5-hydroxytryptamine receptor subtypes brain res bull alpha-adrenoceptor agonists nmda receptor antagonists 5-ht1c receptor antagonists reference benzodiazepine anxiolytics species-specific behavior antipredator defensive behavior accepting optional cookies passive avoidance test common laboratory rodents 5ht drugs mouse cerebral cortex 5-ht1a receptor agonists

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety
         description:The elevated “zero-maze” is a modification of the elevated plus-maze model of anxiety in rats which incorporates both traditional and novel ethological measures in the analysis of drug effects. The novel design comprises an elevated annular platform with two opposite enclosed quadrants and two open, removing any ambiguity in interpretation of time spent on the central square of the traditional design and allowing uninterrupted exploration. Using this model, the reference benzodiazepine anxiolytics, diazepam (0.125–0.5 mg/kg) and chlordiazepoxide (0.5–2.0 mg/kg) significantly increased the percentage of time spent in the open quadrants (% TO) and the frequency of head dips over the edge of the platform (HDIPS), and reduced the frequency of stretched attend postures (SAP) from the closed to open quadrants. In contrast, the anxiogenic drugm-chlorophenyl-piperazine (mCPP; 0.25–1.0 mg/kg) induced the opposite effects, decreasing %TO and HDIPS, and increasing SAP. The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.001–0.1 mg/kg) had no effects on either %TO or HDIPS, but did decrease SAP at 0.01 mg/kg although not at higher or lower doses. Similarly, the 5-HT3 receptor antagonist, ondansetron (0.0001–1.0 mg/kg) decreased SAP and increased %TO at 0.01 mg/kg, but not at other doses. The present data suggest that a combination of the novel “zero-maze” design and a detailed ethological analysis provides a sensitive model for the detection of anxiolytic/anxiogenic drug action.
         datePublished:
         dateModified:
         pageStart:56
         pageEnd:64
         sameAs:https://doi.org/10.1007/BF02244871
         keywords:
            Anxiety
            Elevated zero-maze
            Rat
            Diazepam
            Chlordiazepoxide
            mCPP
            8-OH-DPAT
            Ondansetron
            Head dips
            Stretched attend postures
            Neurosciences
            Pharmacology/Toxicology
            Psychiatry
         image:
         isPartOf:
            name:Psychopharmacology
            issn:
               1432-2072
               0033-3158
            volumeNumber:116
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer-Verlag
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Jon K. Shepherd
               affiliation:
                     name:Wyeth Research (UK) Ltd
                     address:
                        name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Savraj S. Grewal
               affiliation:
                     name:Wyeth Research (UK) Ltd
                     address:
                        name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Allan Fletcher
               affiliation:
                     name:Wyeth Research (UK) Ltd
                     address:
                        name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David J. Bill
               affiliation:
                     name:Wyeth Research (UK) Ltd
                     address:
                        name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Colin T. Dourish
               affiliation:
                     name:Wyeth Research (UK) Ltd
                     address:
                        name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Behavioural and pharmacological characterisation of the elevated “zero-maze” as an animal model of anxiety
      description:The elevated “zero-maze” is a modification of the elevated plus-maze model of anxiety in rats which incorporates both traditional and novel ethological measures in the analysis of drug effects. The novel design comprises an elevated annular platform with two opposite enclosed quadrants and two open, removing any ambiguity in interpretation of time spent on the central square of the traditional design and allowing uninterrupted exploration. Using this model, the reference benzodiazepine anxiolytics, diazepam (0.125–0.5 mg/kg) and chlordiazepoxide (0.5–2.0 mg/kg) significantly increased the percentage of time spent in the open quadrants (% TO) and the frequency of head dips over the edge of the platform (HDIPS), and reduced the frequency of stretched attend postures (SAP) from the closed to open quadrants. In contrast, the anxiogenic drugm-chlorophenyl-piperazine (mCPP; 0.25–1.0 mg/kg) induced the opposite effects, decreasing %TO and HDIPS, and increasing SAP. The 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT; 0.001–0.1 mg/kg) had no effects on either %TO or HDIPS, but did decrease SAP at 0.01 mg/kg although not at higher or lower doses. Similarly, the 5-HT3 receptor antagonist, ondansetron (0.0001–1.0 mg/kg) decreased SAP and increased %TO at 0.01 mg/kg, but not at other doses. The present data suggest that a combination of the novel “zero-maze” design and a detailed ethological analysis provides a sensitive model for the detection of anxiolytic/anxiogenic drug action.
      datePublished:
      dateModified:
      pageStart:56
      pageEnd:64
      sameAs:https://doi.org/10.1007/BF02244871
      keywords:
         Anxiety
         Elevated zero-maze
         Rat
         Diazepam
         Chlordiazepoxide
         mCPP
         8-OH-DPAT
         Ondansetron
         Head dips
         Stretched attend postures
         Neurosciences
         Pharmacology/Toxicology
         Psychiatry
      image:
      isPartOf:
         name:Psychopharmacology
         issn:
            1432-2072
            0033-3158
         volumeNumber:116
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer-Verlag
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Jon K. Shepherd
            affiliation:
                  name:Wyeth Research (UK) Ltd
                  address:
                     name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Savraj S. Grewal
            affiliation:
                  name:Wyeth Research (UK) Ltd
                  address:
                     name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Allan Fletcher
            affiliation:
                  name:Wyeth Research (UK) Ltd
                  address:
                     name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David J. Bill
            affiliation:
                  name:Wyeth Research (UK) Ltd
                  address:
                     name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Colin T. Dourish
            affiliation:
                  name:Wyeth Research (UK) Ltd
                  address:
                     name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Psychopharmacology
      issn:
         1432-2072
         0033-3158
      volumeNumber:116
Organization:
      name:Springer-Verlag
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Wyeth Research (UK) Ltd
      address:
         name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
         type:PostalAddress
      name:Wyeth Research (UK) Ltd
      address:
         name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
         type:PostalAddress
      name:Wyeth Research (UK) Ltd
      address:
         name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
         type:PostalAddress
      name:Wyeth Research (UK) Ltd
      address:
         name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
         type:PostalAddress
      name:Wyeth Research (UK) Ltd
      address:
         name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Jon K. Shepherd
      affiliation:
            name:Wyeth Research (UK) Ltd
            address:
               name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
               type:PostalAddress
            type:Organization
      name:Savraj S. Grewal
      affiliation:
            name:Wyeth Research (UK) Ltd
            address:
               name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
               type:PostalAddress
            type:Organization
      name:Allan Fletcher
      affiliation:
            name:Wyeth Research (UK) Ltd
            address:
               name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
               type:PostalAddress
            type:Organization
      name:David J. Bill
      affiliation:
            name:Wyeth Research (UK) Ltd
            address:
               name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
               type:PostalAddress
            type:Organization
      name:Colin T. Dourish
      affiliation:
            name:Wyeth Research (UK) Ltd
            address:
               name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
      name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
      name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
      name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
      name:Department of Neuropharmacology, Wyeth Research (UK) Ltd, Maidenhead, UK
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(89)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

3.88s.

LINK . SPRINGER . COM {}